




the location of the hotspots, and therefore that of the metastases, by changing the speed of the blood flow.

Also with the help of the zebrafish, they observed that metastatic formation was preceded by the release of tumor-derived extracellular vesicles. These contain proteins, DNA, RNA, and appear to act as veritable scouts for the tumor cells, possibly to prepare their implantation. The research team showed that the behavior of these vesicles in the blood is similar to that of the tumor cells, and also depends on the force of the blood flow.

Finally, the researchers correlated the force of the flow with the action of two proteins located on the tumor cell surface, which can only act when the blood flow is slowed down. The first, CD44, acts like a brake by attaching to the vessel wall. The second,  $\alpha5\beta1$  integrin, enables the cell to stop and to pass through the vessel wall and out of the blood circulation. In zebrafish and mice, the absence of  $\alpha5\beta1$  integrin strongly slows metastatic growth.

*"Overall, this research shows that if we are to prevent the development of metastases, we cannot just focus on the inherent properties of the tumor, its microenvironment or that of the metastases, we must also consider the role played by the biological fluids. Preventing the circulating cells from stopping or from attaching to the vessel wall could, for example, reduce this risk", concludes Goetz.*



Key: Circulation, adherence and extravasation of tumor cells and vesicles to form a metastasis according to changes in blood flow speed. ©Jacky Goetz / Nature Reviews Cancer, 2019

	Cancer cell
	Red blood cell
	Tumor-derived extracellular vesicle
	Endothelial wall remodeling
	Endothelial cell
	Immune cells
	Growing metastasis
	Blood flow
	Extravasation
	Occlusion

	Cancer cell accumulation
	Adhesion
	Adherence proteins: CD44 and $\alpha 5\beta 1$ integrin
	Cell fragmentation by the immune cells
	Intravascular growth
	Blood flow speed (mm/s)

## **Researcher contact**

### **Jacky Goetz**

Inserm Research Director

Tumor Biomechanics team leader

Unit 1109 Molecular ImmunoRheumatology (IRM)

+33 3 68 85 40 11

## **Press contact**

[presse@inserm.fr](mailto:presse@inserm.fr)